English | عربي
  Add to Twitter
Takeda Divests Select Non-Core Assets in Europe to Cheplapharm for Approximately $562 million USD    
• Divestiture strategy on track • Portfolio includes prescription products in Takeda’s Cardiovascular/Metabolic and Anti-inflammatory therapeutic areas along with Calcium